Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.
Clin Infect Dis
; 75(9): 1641-1644, 2022 10 29.
Article
en En
| MEDLINE
| ID: mdl-35510938
ABSTRACT
A patient with end-stage renal disease received 2 doses of dalbavancin for methicillin-resistant Staphylococcus aureus (MRSA) arteriovenous fistula infection and presented 5 weeks later with infective endocarditis secondary to vancomycin, daptomycin, and dalbavancin nonsusceptible MRSA. Resistance was associated with walK and scrA mutations, reduced long-chain lipid content, and reduced membrane fluidity.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Infecciones Estafilocócicas
/
Daptomicina
/
Staphylococcus aureus Resistente a Meticilina
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article